Biogen beat Q1 earnings and revenue estimates, raised rare disease drug sales, and cut its 2025 EPS guidance due to a $165 million collaboration payment.

The Board of Directors of Vertex Securities Limited, at its meeting held today have approved the financial results of the company for the period ended March 31, 2025 - Q4FY25, Q4FY2025, FY2024-25, ...

"It is not some Disney story of just triumph and resilience, it was really hard," Smith tells PEOPLE about his recovery ...

S&P Global reported quarterly adjusted earnings per share of $4.37 on Tuesday, beating the analyst consensus estimate of ...

Vertex Pharmaceuticals outpaced the broader market, closing up 1.19% while major indices mostly tiptoed forward. Over the ...

Shares of Vertex Pharmaceuticals Inc. VRTX rallied 1.19% to $509.50 Wednesday, on what proved to be an all-around positive ...

Kintsugi, a Silicon Valley-based startup that helps companies offload and automate their sales tax compliance, has raised $18 ...

FOX Sports' Joel Klatt joins Colin Cowherd to dive into what led to Shedeur Sanders dropping to the fifth round and how he ...

“Kintsugi brings innovative AI-enabled capabilities to address the needs of the indirect tax market in new and creative ways,” stated Chirag Patel, Vertex Chief Strategy Officer. “Through the IP ...

SAN FRANCISCO, April 30, 2025 /PRNewswire/ -- Kintsugi AI, a cutting-edge tax automation platform, announced today a strategic backing from Vertex Inc. This investment will accelerate Kintsugi's ...

Novartis is buying Regulus for $800 million, picking up the biotech's experimental kidney drug that's based off a ...

Iovance Biotherapeutics ( IOVA 0.98%) and CRISPR Therapeutics ( CRSP 3.42%) are two incredibly innovative biotechs, but this hasn't translated into strong performances recently. Both stocks have ...